Table 1 |
|||||||
|
Overall statistical power of the study for KCNA5 rs10744676 SNP in each analyzed disease subtype at the 5% significance level assuming an additive effect model and a minor allele (rs10744676*C) frequency = 0.10 (MAFCEU) |
|||||||
|
Phenotype |
|||||||
|
|
|||||||
|
Statistical power (%) |
SSc |
lcSSc |
dcSSc |
ACA+ |
ATA+ |
Fib+ |
PAH+ |
|
|
|||||||
|
OR = 0.62 |
100 |
100 |
99 |
100 |
96 |
99 |
95a |
|
OR = 0.48 |
100 |
100 |
100 |
100 |
100 |
100 |
100b |
|
OR = 0.79 |
96 |
91 |
67 |
77 |
59 |
71 |
45c |
|
|
|||||||
|
aReference OR, 0.62, except for the PAH+ group, in which OR = 0.47. bReference OR (lower previously reported 95% CI) = 0.48, except for the PAH+ group, in which OR = 0.32. cReference OR (upper previously reported 95% CI) = 0.79, except for the PAH+ group, in which OR = 0.71. SSc, systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ACA+, anti-centromere autoantibody-positive patients; ATA+, anti-topoisomerase autoantibody-positive patients; Fib+, lung fibrosis-positive patients (HRCT); PAH+, pulmonary arterial hypertension-positive patients (right-heart catheterization). |
|||||||
|
Bossini-Castillo et al. Arthritis Research & Therapy 2012 14:R273 doi:10.1186/ar4124 |
|||||||